• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Frances unveils drug regulation overhaul

Frances unveils drug regulation overhaul

July 15, 2011
CenterWatch Staff

Health minister Xavier Bertrand says new regulation will strengthen pharmacovigilance, create greater transparency and more declaration of interests at all levels of regulation and government, according to InPharm.

A controversy over the drug Mediator (benfluorex) caused distrust of pharmaceutical industry practices in France, with Servier’s alleged close connections with doctors and regulators blamed for the drug staying on the market.

Médiator was allowed to remain on the market in France long after it had been withdrawn in other European countries because of safety concerns. Servier’s drug was frequently prescribed off-label for weight loss in France until it was withdrawn in November 2009, after safety concerns were brought to light. Numerous retrospective studies have concluded that the drug could have caused from 500 to 2,000 deaths in France, mainly from damage to heart valves.

After a long public consultation, drug regulation will now be extensively overhauled. Among the many new measures will be assessments of whether or not new drugs offer real benefits over existing ones.

Healthcare professionals also will receive more education, but pharma companies will be banned from financing any continuing professional development. Pharma companies could be fined if they fail to declare relationships with other organizations, and new stricter controls on off-label prescribing will also be introduced.

Work already has begun on reviewing 19,000 drugs currently approved in France, of which 12,000 are on the market. The health minister predicts that many existing drugs will be withdrawn because they cannot demonstrate non-inferiority to other treatments.

The medicines regulator (AFSSAPS) also has been condemned in the media for its failure to act and will now be re-modeled as the National Agency for the Safety of Medicines (ANSM).

Health minister Bertrand has acknowledged “serious failures in the functioning of our drug system,” but said Servier, rather than the French government, will have to compensate victims.

Dominique Maraninchi, now head of AFSSAPS, said the newly named agency will need a 20% bigger annual budget to implement the reforms.

France’s pharmaceutical industry association LEEM has welcomed most of the proposals but has plans to restrict visits by sales representatives, and place a ban on pharma funding for medical education. LEEM said it is very worried by the proposed reforms, which it fears will create ‘uniquely restrictive practices’ in France and create rules that are incomprehensible for international companies and bad for jobs in the sector.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing